alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › antibody-lecanemab

antibody-lecanemab

2 studies tagged antibody-lecanemab, dated 2025-02-01 to 2026-06-22. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer's disease: a target trial emulation 2026-06-22
  2. [Pathophysiology and Clinical Presentation of Amyloid-Related Imaging Abnormality Induced by Anti-Amyloid-β Antibody Lecanemab] 2025-02-01

Studies

2 studies carry this tag.

Date range

2025 to 2026

Top journals

  • Alzheimer's research & therapy 1
  • Brain and nerve = Shinkei kenkyu no shinpo 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer's disease: a target trial emulation

    ✓ Peer-reviewed alzhub usefulness score 78 out of 100. Alzheimer's research & therapy 2026-06-22 Treatments

    Compared with an AChEI-based conventional care strategy, lecanemab initiation was associated with comparable treatment persistence and lower observed risks of BPSD, emergency visit as well as reduced use of psychotropic and infection-related medications in exploratory analyses.

  2. [Pathophysiology and Clinical Presentation of Amyloid-Related Imaging Abnormality Induced by Anti-Amyloid-β Antibody Lecanemab]

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain and nerve = Shinkei kenkyu no shinpo 2025-02-01 Treatments

    Lecanemab, the first monoclonal antibody drug targeting amyloid beta (Aβ), was approved for slowing the progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in the United States and Japan.

All topic tags with their study counts